Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Shares of Amgen Inc. AMGN slipped 1.01% to $258.59 Monday, on what proved to be an all-around mixed trading session for the ...

Here's why Amgen increased its land holdings in New Albany, even though the pharma giant has plenty of room for expansion on ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, ...

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Amgen (AMGN – Research Report), with a ...

Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.